The FDA approved insulin icodec (Awiqli) as the first once-weekly, long-acting basal insulin for glycemic control in adults ...
Novo Nordisk’s icodec-abae is now approved in the US for type 2 diabetes only, after a prior rejection partly due to concerns about hypoglycemia in type 1 diabetes.
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Insulin efsitora was noninferior to once-daily insulins ...
SUPER-1 evaluated GZR4 in insulin-naïve Chinese adults with T2DM, while SUPER-2 assessed those previously treated with basal insulin.
Type 2 diabetes, linked to insulin resistance, affects a significant portion of the American population, many undiagnosed. Pre-diabetes, also caused by insulin resistance, often progresses to Type 2 ...
The FDA approved a once-weekly, long-acting basal insulin for adults with type 2 diabetes as an alternative to daily basal ...
The FDA has approved Awiqli, the first once‑weekly long‑acting basal insulin, for adults with type 2 diabetes, which offers ...
Some patients with type 2 diabetes will be able to switch from daily insulin injections to this first-of-its-kind once-weekly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results